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Summary
Objective: To evaluate the effect of waiting time on health and quality of life outcomes and costs of medication in total hip replacement (THR)
patients in a randomized clinical trial.
Methods: 395 THR patients were recruited into the study. When placed on the waiting list, patients were randomized into a short (3 months)
or a non-ﬁxed waiting time (NFWT) (>3 months) group. In the ﬁnal analyses 309 patients (179 women) with a mean age of 65 years were
included. Health-related quality of life (HRQoL) (generic 15D), and pain and function (modiﬁed Harris Hip Score (HHS)) were calculated
when placed on the waiting list, at hospital admission, and at 3 and 12 months postoperatively. The costs of disease-speciﬁc medication
were calculated at the same measurement points. All analyses were performed using the intention-to-treat (ITT) principal.
Results: Of the recruited patients, 309 (78%) completed the follow-up (short group 140 and non-ﬁxed group 169 patients). The mean waiting
time was 74 days in the short and 194 days in the NFWT groups. In the ITT analyses there were no statistically signiﬁcant differences between
the groups in the weekly use and costs of medication, HRQoL or HHS at baseline, at admission, or 3 or 12 months after surgery. The only
difference was in total medication costs during the waiting time period, at EUR 83 and 171, respectively.
Conclusions: The length of the waiting time did not generate different effects on the studied health and quality of life outcomes of the randomized
groups. However, those in short waiting time group reached earlier better HRQoL.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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According to the Health 2000 Health Examination Survey in
Finland, 12% of the population aged over 65 had hip arthri-
tis1, while 8460 total hip replacements (THRs) were per-
formed in 2004 with the median waiting time to surgery
being 153 days. Between 1987 and 2004, the THR rate
rose on average 5% annually2. In 2005, the Finnish Social
Insurance Institution paid EUR 85 million in drug reimburse-
ments to 990,637 patients with musculoskeletal diseases,
with the mean cost per patient being euro (EUR) 86 per
year3.*Address correspondence and reprint requests to: Ulla
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1144Earlier studies have established that arthritis causes pain,
reduces the range of motion, and creates difﬁculties in partici-
pating in daily activities, which in turn affect quality of life. Be-
cause the waiting times for surgery are long, the disease
becomes an increasingly chronic burden to patients4e7. More-
over, the duration of conservative treatment and the use of
medication (analgesics and anti-inﬂammatory drugs) increase
with longer waiting time. Prior studies have demonstrated that
poorer health status preoperatively is predictive of higher out-
of-pocket costs for patients during the ﬁrst year postopera-
tively8, and waiting more than 6 months is associated with
highermean total costswhile longerwaiting times results inde-
terioration in physical function while waiting7.
The aim of this prospective randomized controlled trial was
to identify the effects of waiting time on health and health-re-
lated quality of life (HRQoL) outcomes and the use and costs
of disease-speciﬁc medication (DSM) among two patients
group; a short waiting time group (SWT) (3 months) and
a non-ﬁxed waiting time (NFWT) group (>3 months). Mea-
surements took place when ﬁrst placed on the waiting list,
at admission, and 3 and 12 months after the THR.
1145Osteoarthritis and Cartilage Vol. 17, No. 9To our knowledge no prior studies have looked at the ef-
fect of waiting time on HRQoL and the use and costs of
DSM among hip replacement patients in a randomized
study design. The question of whether the length of waiting
time for THR affects the use and costs of medication and
health and quality of life outcomes is a contested issue.
MethodsDATA COLLECTIONBetween August 2002 and November 2003, 513 THR patients in three
Finnish hospitals were invited to participate in the study: two of the hospitals
(the Surgical Hospital and Jorvi Hospital) are part of the Helsinki University
Central Hospital, while the third is the Coxa Hospital for Joint Replacement.
Patients were recruited into the study through contact with orthopedic and
practice staff.
The key inclusion criteria were the need for a primary THR due to osteo-
arthritis of the hip joint as evaluated by the hospital surgeon, the patient was
aged 16 or older and placed on the waiting list in a research hospital, and the
patient was willing and mentally able to participate in the study. The key ex-
clusion criteria were patients with rheumatoid arthritis, fractures, and congen-
ital haemophilia or congenital deformities.RANDOMIZATIONWhen placed on the hospital waiting list, patients were randomly as-
signed to one of two groups: (1) a SWT with a maximum wait of 3Invited to participat
Excluded (n=118)
Refused (n=103)
Did not understand
Finnish or Swedish (n=2)
Other reasons (n=13)
Randomized (n=
Allocated to Short WT group
(n=174)
Completed baseline measurement
(n= 168)
Lost to follow-up (n=28)
Surgery was cancelled (n=4)
Exited the queue (n=1)
Died (n= 2)
Operated elsewhere (n=1)
Did not return the form (n=20)
Analysed (n= 140)
Fig. 1. Flow of patientsmonths, or (2) a NFWT with surgery performed according to the hospital’s
routine procedure, with the waiting period measured from the date the pa-
tient was added to the waiting list to the date of admission for surgery.
The number of patients placed on the waiting list varied from 1 month
to another, being speciﬁc to each hospital. Therefore, no advance esti-
mate could be made of the number of patients to be placed on the list.
The patients randomized into the SWT group could only be operated
on in one of four operating periods during the year, and only half of the
hospital’s 1-month surgical capacity could be allocated to the SWT group,
so the number of SWTs was restricted and determined speciﬁcally for
each hospital.
Patients were recruited into the study in over three (for one of the hospi-
tals) or four recruitment periods (for the other two hospitals), each period last-
ing 3 months in order to avoid the waiting time for the SWT group exceeding
3 months. Patients in the SWT group were operated within 2 weeks following
the end of each recruitment period. The size of the NFWT group was not re-
stricted so as to ensure that all eligible patients placed on the waiting list had
an opportunity to be recruited to the study. Randomization took place during
the whole recruitment period (3 months), allowing everyone the possibility of
a SWT. The two patient groups therefore differed in size.
Computer-generated randomization sequences were produced by the
National Research and Development Centre for Welfare and Health and sup-
plied to the hospitals using consecutively numbered and sealed opaque en-
velopes. The patient’s named nurse assigned participants to their groups
after the decision for surgery had been made. The randomization envelops
contained information on whether the patient belonged to the SWT or
NFWT group. Surgeons were blind to patient allocation. For ethical reasons
double-blinding was not possible.
Patients completed a self-administered questionnaire when placed on the
waiting list, at admission, and at 3 and 12 months postoperatively. Thee (n=513)
395)
Allocated to Non-fixed WT group
(n= 221)
Completed baseline measurement
(n= 216)
Lost to follow-up (n=47)
Surgery was cancelled (n=8)
Exited the queue (n=3)
Died (n=5)
Operated elsewhere (n=6)
Did not return the form (n=25)
Analysed (n=169)
through the trial.
Table I
Baseline characteristics of randomized groups and those lost to follow-up
Characteristics at baseline SWT (n¼ 145) NFWT (n¼ 175) Lost to follow-up
(n¼ 64)
P-value*
Age, years (meanSD) 66 9.8 64 10.1 68 10.1 0.053
Females [n, (%)] 88 (49.2) 91 (52.3) 38 (62.3) 0.539
Housing [n, (%)]
Living alone 50 (33.6) 45 (26.5) 20 (33.9) 0.313
Basic education [n, (%)]
Lower level 118 (79.2) 133 (78.7) 46 (78.0) 0.494
Comorbidity, yes [n, (%)] 103 (69.1) 116 (68.2) 40 (67.8) 0.504
Medication to arthritis, yes [n, (%)] 136 (91.3) 149 (87.6) 56 (94.9) 0.136
Medication costs V/weekSD 5.4 5.8 6.3 7.0 5.5 7.2 0.997
BMIy SD 27.9 3.9 27.7 3.8 27.7 4.6 0.865
HHSz SD 43.9 13.5 44.09 14.4 44.3 12.9 0.853
Pain scoreSD 16.8 7.6 17.4 6.8 16.2 7.0 0.388
Function scoreSD 27.1 8.6 27.2 9.0 27.7 8.1 0.612
15D score** (meanSD) 0.767 0.09 0.764 0.12 0.753 0.01 0.295
*Between patients who completed all questionnaires and those lost to follow-up.
yBody mass index (kg/m2).
zThe scale 0e91, worst to best.
**The scale 0e1, worst to best.
1146 U. Tuominen et al.: The effect of waiting time on health and quality of life outcomesquestionnaires were either distributed to the patients at the hospital or in
some cases mailed to patients, as happened with one hospital for the third
and fourth questionnaires. All questionnaires were returned by post. Com-
mon guidelines for administering the questionnaires were provided in each
hospital. The patients completed a sociodemographic form, reported their
medication and comorbidities as diagnosed by a medical doctor, and com-
pleted the disease-speciﬁc modiﬁed Harris Hip Score (HHS) and a separate
questionnaire for HRQoL. Each patient provided informed consent. The
study was approved by the Helsinki University Central Hospital Surgery
Ethics Committee.MEASUREMENT INSTRUMENTSHRQoL was measured by the generic 15D instrument. The 15D is com-
posed of 15 dimensions: moving, vision, hearing, breathing, sleeping, eating,
speech, eliminating, vitality, usual activities, mental function, discomfort and
symptoms, depression, distress, and sexual activity. Each dimension has
ﬁve ordinal levels to choose from. The 15D can be used as a proﬁle measure
or to give a single index score by means of population-based preference
weights. The index score (15D score) ranges from 0 (dead) to 1 (completelyFig. 2. The distribution of patients by waiting time in the randomized
groups.healthy)9. Completing the 15D questionnaire takes 5e10 min and it de-
scribes the HRQoL of the respondent at present. A difference of >j0.03j in
the 15D score is clinically important in the sense that on average people
can feel the difference10. In most of the important properties (reliability, con-
tent validity, sensitivity in terms of discriminatory power and responsiveness
to change) the 15D compares at least equally with other similar instruments
that produce a valuation-based single index number10e14.
By using the mean 15D scores from each measurement point and assum-
ing a linear change in the scores between the measurement points we also
estimated the possible gain in quality-adjusted life years (QALY gain) for
both groups within the observation period.
The disease-speciﬁc modiﬁed HHS was used to measure hip pain and
function. The self-report HHS consists of two sections: pain (0e44 points)
and functional activities of daily living and gait (0e47). The total score ranges
from 0 to 91, with higher scores representing better health states15. A further
9 points of the total HHS would normally be assigned to describing deformity
and range of motion, but were excluded because these items could not be
measured in a patient self-report questionnaire. The performance of self-re-
ported HHS is comparable to that of surgeon-assessed HHS and has shown
to be less burdensome to patients than physician-administered HHS16. The
HHS and 15D score serve as measures of disease severity at baseline
(preoperatively).
The use of DSM (analgesics and anti-inﬂammatory drugs) during the
week preceding every measurement point was measured based on self-re-
port. The unit costs of medication per tablet were obtained from CD-Phar-
macy17. The costs of medication during the waiting period were calculated
as a product of the weeks spent on the waiting list and the medication costs
per week. The calculations for medication costs were made at each of the
four measurement points.STATISTICAL ANALYSISThe sample size estimate was based on the primary outcome variable
15D. A subgroup of 177 patients would provide the 80% power (two-tailed
a error 5%) to detect clinically important differences (D0.03) in the 15D score
between the randomized groups.
Primary analyses were conducted with an intention-to-treat (ITT)
principle18, so that patients were followed in the groups to which they
were randomly allocated. Also a supplementary per-protocol analysis
was carried out at admission by excluding the patients from SWT group
who were admitted beyond the short waiting time (waiting time> 3
months). When comparing the mean scores of 15D, total HHS, pain, func-
tion and costs of DSM at the various points of follow-up between SWT and
NFWT, general linear model for repeated measures was used. Univariate
(tests of within-subject effects) P-values were calculated, while a P-value
<0.05 was considered statistically signiﬁcant. Also the mean differences,
standard deviations and conﬁdence intervals (CIs) of 95% of the variables
15D, total HHS, pain, function and costs of DMS were presented for the
estimated effect.
Descriptive characteristics at baseline in the randomized groups and the
patients who were lost to follow-up were compared using either the F-test or
Table II
Outcomes at admission, ITT-analysis
Outcome measure SWT mean (SD)
(n¼ 139e140)
NFWT mean (SD)
(n¼ 167e169)
Mean difference 95% CI P-value
15D score* 0.768 (0.107) 0.769 (0.107) 0.001 0.022 to 0.024 0.931
Self-report HHSy 42.99 (15.32) 41.73 (14.08) 1.262 5.233 to 1.816 0.456
HHS pain score 17.63 (7.64) 17.14 (8.55) 0.493 2.332 to 1.346 0.602
HHS function score 25.86 (9.08) 24.79 (8.42) 1.067 3.051 to 0.915 0.29
Costs of medicationz 5.56 (6.80) 5.63 (6.22) 0.793 1.399 to 1.557 0.916
Costs of medication** 81.3 (129.54) 171.3 (264.36) 88.49 42.49 to 134.90 0.000***
Waiting time, days 74 (145) 194 (175) 117.80 93.03 to 142.57 0.000***
***P< 0.001.
*The scale 0e1, worst to best.
yThe scale 0e91, worst to best.
zWeekly costs of medication in EUR (EUR is 1.6 US$).
**Medication costs during the waiting time.
1147Osteoarthritis and Cartilage Vol. 17, No. 9the chi-squared test, depending on whether the variable was on a continuous
or nominal scale.
Missing values on the 15D were replaced if a minimum of 80% of dimen-
sions had been completed, using a regression model with the patient’s re-
sponses for other dimensions, age and gender as explanatory variables11.
Data analyses were performed using SPSS versions 14 and 16 for Windows.Results
Of the 513 eligible patients invited to participate in the
study, 118 refused to participate and were excluded. Their
mean age was 70 years (SD 11) and 64% were women.
The most frequently quoted reasons for refusal were being
too tired or unwillingness to complete questionnaires. Thus,
395 patients after providing a signed informed consent were
randomly allocated to either the SWT (n¼ 174) or NFWT
(n¼ 221) group. Of these patients, 86 were lost to follow-
up during the waiting time and were not included in the ﬁnal
analyses. Of these patients 11 did not return the question-
naire at baseline, although they had signed informed con-
sent and were randomized, seven were operated on
elsewhere, operations for 12 patients were canceled, and
seven died while waiting and 45 did not return the question-
naire at admission. All analyses are based on 309 (78%)
patients (179 women) with a mean (SD) age of 65 (9.9;
range; from 33 to 87) years, of which 140 were in the
SWT and 169 in the NFWT group (Fig. 1).BASELINE CHARACTERISTICSThe baseline characteristics of the groups were similar
and are reported in Table I. The mean (SD) 15D score
in the SWT group was 0.767 (0.09) and 0.764 (0.12)Table I
Outcomes at admission, p
Outcome measure SWT mean
(SD) (n¼ 92)*
NFWT mean
(SD) (n¼ 170)
15D-score 0.764 (0.11) 0.770 (0.11)
Self-report HHS 42.95 (16.27) 41.73 (14.0)
HHS pain score 17.42 (8.18) 17.14 (8.56)
HHS function score 25.90 (9.47) 24.80 (8.42)
Costs of medicationy 5.22 (6.74) 5.63 (6.22)
Waiting time days 59.28 (21.40) 218.50 (140.35)
***P< 0.001.
*49 SWT patients admitted beyond SWT were excluded.
yWeekly costs of medication in EUR (EUR is 1.6 US$).in the NFWT group; the difference was not statistically sig-
niﬁcant or clinically important (P¼ 0.295). The mean (SD)
total HHS was 43.9 (13.6) and 44.1 (14.1) in the SWT
and NFWT group, respectively (P¼ 0.853). The percentage
of patients receiving DSM was 91% (n¼ 136) in the SWT
and 89% (n¼ 149) in the NFWT group. The mean weekly
medication costs were EUR 5.4 and EUR 6.3 in the SWT
and NFWT groups, respectively. The difference was not
statistically signiﬁcant (Table I).
A comparison between patients who completed the
questionnaire and those who were lost to follow-up showed
no statistically signiﬁcant differences between the groups
(Table I).OUTCOMES AND WAITING TIMEAt admission there was a statistically signiﬁcant differ-
ence in mean waiting time between the groups: 74 (145)
days in the SWT and 194 (175) days in the NFWT group
(95% CI: 93.03e142.57, P< 0.001) (Fig. 2). There were no
statistically signiﬁcant differences between the groups in the
mean 15D score, total HHS, pain and function or in the
weekly cost of medication. However, due to a shorter wait-
ing time the total cost of DSM during the waiting period was
lower in the SWT group (EUR 81.3) than in the NFWT group
(EUR 171.3) (95% CI: 42.49e134.90, P< 0.001) (Table II).
A per-protocol analysis was performed as a supplemen-
tary analysis. In the SWT group (n¼ 92), those compliant
with allocated waiting time 59 (21) days and all patients
(n¼ 170) in the NFWT group were included in the analysis.
Similar results were obtained in a per-protocol analysis as in
ITT analysis (Table III).II
er-protocol analysis
Mean difference 95% CI P-value
0.004 0.023 to 0.032 0.733
1.251 5.198 to 2.766 0.548
0.283 2.432 to 1.866 0.795
1.106 3.442 to 1.230 0.351
0.41 1.277 to 2.098 0.632
159.211 137.79 to 180.635 0.000***
Table IV
Descriptive statistics of the outcomes in SWT and NFWT groups; mean and standard deviation
Outcome At baseline At admission 3 months postoperatively 1-year postoperatively
SWT NFWT SWT NFWT SWT NFWT SWT NFWT
15D
Mean 0.770 0.779 0.772 0.775 0.852 0.859 0.857 0.873
SD 0.090 0.100 0.090 0.090 0.090 0.100 0.110 0.110
Total HHS
Mean 43.75 43.05 43.55 41.82 67.02 67.12 72.18 74.57
SD 13.78 14.58 15.27 14.48 16.54 17.15 16.91 16.9
Function score
Mean 26.68 26.19 26.11 24.93 34.93 35.05 39.05 39.24
SD 8.73 8.95 8.97 8.56 8.41 9.04 7.67 8.5
Pain score
Mean 16.82 17.43 17.63 17.13 32.4 32.75 33.57 35.1
SD 7.6 6.8 7.6 8.55 10 9.5 9.78 10.06
Costs of medication (V)
Mean 5.06 6.41 5.31 5.57 1.59 1.96 0.8 0.98
SD 5.78 7.23 6.73 6.4 4.12 4.47 2.45 2.71
1148 U. Tuominen et al.: The effect of waiting time on health and quality of life outcomesOUTCOMES AFTER THRThe use and costs of medication had decreased in both
groups at 3 months and 1 year after the THR: 43%
(n¼ 55) in the SWT and 48% (n¼ 71) in the NFWT group
reported using medication for arthritis. In the SWT group
the weekly costs at 3 months were EUR 1.58 and in the
NFWT group EUR 1.96 and after 1 year EUR 0.80 and
EUR 0.98, respectively. The differences were statistically
signiﬁcant between different measurement points
(F¼ 63.08; P< 0.001), but not between the randomized
groups (F¼ 1.08; P ¼ 0.372).
At 3 months the mean 15D score was 0.852 in the SWT
and 0.859 in the NFWT group, and after 1 year 0.856 and
0.873, while the mean total HHS was after 3 months
67.02 and 67.12, respectively and after 1 year 72.18 and
74.57, respectively. The differences between the groups
are not statistically signiﬁcant (Table IV). There were statis-
tically signiﬁcant differences between different measure-
ment points, but not between the randomized groups
(Table V).
There was an improvement from 3 months to 12 months
postoperatively in the mean 15D score and total HHS, pain
and function and a decrease in the cost of medication in
both groups. SWT resulted in a gain of 0.028 QALYsTable V
Effect of the waiting time in the randomized groups. General linear
model, repeated measures analysis, tests of within-subjects effect
Measurement
instrument
Source F P-value
15D Time 207.324 0.000*
Time randomized group 0.694 0.531y
HHS Time 470.763 0.000*
Time randomized group 1.429 0.239y
Function score Time 308.701 0.000*
Time randomized group 0.703 0.511y
Costs of
medication
Time 86.104 0.000*
Time randomized group 1.04 0.365y
*Time effect e differences between the four measurement
points.
yGroup effect e differences between randomized groups.(area between the curves in Fig. 3) during the observation
period.Conclusions
Scientiﬁc evidence on the relationship between waiting
time and THR outcomes is inconsistent and the absence
of randomized trials has prevented an assessment of
whether longer waiting is somehow related to health and
quality of life outcomes. To our knowledge, the present
study is the ﬁrst to assess the use and costs of DSM in
THR patients randomly allocated to short and NFWT
groups. The study also analyzed whether the length of the
waiting time was related to HRQoL, hip pain and function
as measured by the 15D and HHS, respectively.
The main ﬁnding was that the time spent on the waiting
list was not related to the weekly use and costs of DSM,
with no differences found between the randomized groups.
The weekly costs were almost identical in both groups at
each of the four measurement points. In an earlier study
among these patients it was found that they used very little
health and social services during the waiting time and only
a minority of patients received visits to their home from
nurse, chiropodist or physician with no statistically0,5
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0,7
0,75
0,8
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0,9
0,95
1
0 100 190 221 311 465 586
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Fig. 3. The QALY gain (area between the curves) due to short
waiting time during the observation period.
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Similarly, the mean HRQoL scores and pain and function
scores were almost identical in both groups at each of
the four measurement points, and reached their highest
values 12 months postoperatively. However, the SWT re-
sulted in a small QALY gain of 0.028, and reached better
quality of life 3 months earlier than those in the NFWT
group.
In this study, patients’ HRQoL at baseline was deterio-
rated and they had pain and difﬁculties in functioning and
daily activities. However, the length of waiting time alone
did not affect HRQoL or pain and function scores, which
is in line with the ﬁndings of some earlier studies4,5,7,20,21.
However THR has been found to be effective12,13,22,23,
with this study also showing signiﬁcant improvement in
HRQoL and in pain and function 3 and 12 months postop-
eratively in both randomized groups.
To our knowledge no studies have so far been published
on the effect of waiting time on the use and costs of DSM.
Fielden et al.6 estimated the costs and outcomes of the
waiting time for THR in a prospective study. They found
that waiting more than 6 months was associated with higher
total costs and deterioration in physical function while wait-
ing. These cost results are not comparable to ours, as they
estimated all costs during the waiting period6.
The strengths of this study were that the patients awaiting
THR were prospectively followed from the time of being
placed on the waiting list to admissiondwith waiting times
recorded preciselydand for a further year of follow-up
postoperatively, providing evidence of the effect of WT on
pre- and postoperative health status. Further the patients
were randomly assigned to either a SWT or NFWT group.
The ﬁndings were based on the simultaneous use of pa-
tient-reported generic and disease-speciﬁc instruments as
outcome measures. Also the results based on ITT and
per-protocol analyses indicated that there were no statisti-
cal signiﬁcant differences in health outcomes between the
randomized groups. This was further tested with repeated
measures analyses. The within-subject test indicated that
there was a signiﬁcant time effect, i.e., the outcomes did
change over time, but the changes were identical, which
is consistent with the ﬁnding that the interaction was not
signiﬁcant.
Some limitations pertain to this study. First, patients
who refused to participate the study were older than
those in the study groups. Second, medication informa-
tion was obtained only from patient self-reports, while
there was no distinction between self-care and prescrip-
tion medication. For temporary medication we used
mean dosages. Third, a total of 49 patients in the SWT
group waited more than 3 months. The reasons were
hospitals’ limited capacity to carry out THR within the 3
months waiting time period or the patient’s unwillingness
to have THR within 3 months. Due to these factors, the
differences between the randomized groups may have
been underestimated. However the primary analysis
was based on the ITT principle to address the question
of clinical effectiveness and to avoid the bias associated
with a non-random loss of participants. In addition the
supplementary per-protocol analysis at admission where
the SWT patients who were admitted beyond SWT were
excluded from the analysis e supported the main ﬁnd-
ings and did not show a statistically or clinically important
difference in HRQoL between randomized groups.
According to this study the length of the waiting time, at
least as realized in practice in this study, did not result in
different health outcomes in the randomized groups in threecross-sectional follow-up measurements from baseline to 1-
year postoperatively. The length of the waiting time re-
ﬂected in the total medication costs of the waiting period
and in a small QALY gain in the SWT, as it reached the
same HRQoL level as the NFWT group on average 3
months earlier.Conﬂict of interest
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